Precigen to participate in the stifel 2022 virtual cell therapy summit

Germantown, md. , june 27, 2022 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that helen sabzevari, phd, president and ceo of precigen, will participate in a virtual panel discussion titled, "targeted t cell therapies, including autologous car t, tcr and more" on thursday, june 30, 2022, at 1:00 pm et at the stifel 2022 virtual cell therapy summit.
PGEN Ratings Summary
PGEN Quant Ranking